OneAscent Financial Services LLC Acquires 1,495 Shares of GSK plc (NYSE:GSK)

OneAscent Financial Services LLC grew its holdings in GSK plc (NYSE:GSK) by 25.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,408 shares of the pharmaceutical company’s stock after acquiring an additional 1,495 shares during the period. OneAscent Financial Services LLC’s holdings in GSK were worth $251,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of GSK. Sunbelt Securities Inc. raised its holdings in GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 302 shares during the period. Indiana Trust & Investment Management Co raised its stake in shares of GSK by 200.0% in the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock worth $25,000 after buying an additional 500 shares during the period. Crews Bank & Trust purchased a new position in shares of GSK during the 4th quarter valued at about $26,000. ST Germain D J Co. Inc. grew its stake in shares of GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 522 shares during the period. Finally, Sierra Ocean LLC purchased a new stake in GSK in the 4th quarter worth approximately $32,000. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Performance

GSK opened at $36.49 on Friday. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The stock has a market capitalization of $75.53 billion, a price-to-earnings ratio of 22.95, a PEG ratio of 1.12 and a beta of 0.56. The company has a fifty day moving average of $37.63 and a 200 day moving average of $36.59. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.93.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. As a group, sell-side analysts forecast that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be issued a dividend of $0.3932 per share. This represents a $1.57 annualized dividend and a dividend yield of 4.31%. This is a boost from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. GSK’s dividend payout ratio is 98.74%.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Morgan Stanley started coverage on shares of GSK in a research note on Wednesday, February 12th. They set an “equal weight” rating on the stock. Seven investment analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat, GSK presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.